SkyKnight Capital has entered into a definitive agreement to invest in Apex Infusion, as announced in a news release.

Founded in 2006, Apex Infusion is headquartered in Signal Hill, California, and operates a network of ambulatory infusion suites and in‑home care services.

SkyKnight Capital, founded in 2015, has offices in Burlingame, California and New York, and focuses on healthcare and a few other sectors.

The firm plans to invest $25 million to $250 million or more to acquire 25% to 75% or higher equity ownership.

Apex’s management team will retain a significant ownership stake, while FFL Partners, an existing investor, will remain a minority investor.

Specific terms of the investment were not disclosed, leaving the exact structure and valuation unknown.

The acquisition is expected to strengthen Apex’s expansion into new markets and enhance its service offerings.

Both parties anticipate a joint effort to scale operations and improve patient access to infusion therapies.